Skinner-Adams Tina S, McCarthy James S, Gardiner Donald L, Hilton Petrina M, Andrews Katherine T
Malaria Biology Laboratory, Australian Centre for International and Tropical Health and Nutrition, Queensland Institute of Medical Research and School of Population Health, University of Queensland, St. Lucia, Queensland, Australia.
J Infect Dis. 2004 Dec 1;190(11):1998-2000. doi: 10.1086/425584. Epub 2004 Nov 3.
Recent studies have indicated that antiretroviral protease inhibitors may affect outcome in malarial disease. We have investigated the antimalarial activities of 6 commonly used antiretroviral agents. Our data indicate that, in addition to the previously published effects on cytoadherence and phagocytosis, the human immunodeficiency virus (HIV)-1 protease inhibitors saquinavir, ritonavir, and indinavir directly inhibit the growth of Plasmodium falciparum in vitro at clinically relevant concentrations. These findings are particularly important in light of both the high rate of malaria and HIV-1 coinfection in sub-Saharan Africa and the effort to employ highly active antiretroviral therapy in these regions.
近期研究表明,抗逆转录病毒蛋白酶抑制剂可能会影响疟疾的病情转归。我们研究了6种常用抗逆转录病毒药物的抗疟活性。我们的数据表明,除了先前已发表的对细胞黏附和吞噬作用的影响外,人类免疫缺陷病毒(HIV)-1蛋白酶抑制剂沙奎那韦、利托那韦和茚地那韦在临床相关浓度下可直接抑制恶性疟原虫在体外的生长。鉴于撒哈拉以南非洲地区疟疾和HIV-1合并感染率很高,以及在这些地区采用高效抗逆转录病毒疗法的努力,这些发现尤为重要。